2 results
Approved WMOCompleted
Part A: 52-week double-blind treatment phasePrimary* To investigate the efficacy of sirukumab (100 mg q2w for 12 months) as compared to placebo, each administered in addition to a 6-month prednisone treatment regimen Secondary* To assess cumulative…
Approved WMORecruiting
The three key outcome measurements and challenges of this proof of concept study are to achieve a decrease in ongoing HO bone formation, decrease in numbers of disease *flare-up* episodes and to prevent the continuation of FOP induced contractures.…